. Author manuscript; available in PMC: 2016 Apr 3.

Published in final edited form as: J Proteome Res. 2015 Mar 9;14(4):1968–1978. doi: 10.1021/acs.jproteome.5b00068

Table 2. List of Differentially Expressed CF Peptides between Healthy Control Samples and Pancreatic Cancer or Chronic Pancreatitis^a.

accession no.	protein name	CF peptide^b	N/SR	CP/SR	PC/SR
Q86TH1	ADAMTS-like protein 2	DFTLn*ETVNSIFAQGAPR	0.71 ± 0.26	1.15 ± 0.37^c	1.01 ± 0.28^c
P43652	Afamin	DIENFn*STQK	0.54 ± 0.33	1.20 ± 0.67^c	1.28 ± 0.85^c
		YAEDKFn*ETTEK	0.40 ± 0.23	1.29 ± 0.85^c	1.42 ± 1.09^c
P02765	Alpha-2-HS-glycoprotein	AALAAFNAQNn*GSNFQLEEISR	0.82 ± 0.26	1.43 ± 0.53^c	1.14 ± 0.16^c
P01008	Antithrombin-III	SLTFn*ETYQDISELVYGAK	0.77 ± 0.28	1.30 ± 0.75	1.23 ± 0.41^c
		AAINKWVSn*KTEGR	0.68 ± 0.40	1.41 ± 0.69^c	1.17 ± 0.52^c
		LGACn*DTLQQLMEVFK	0.82 ± 0.43	1.19 ± 0.58	1.14 ± 0.33^c
P02749	Beta-2-glycoprotein 1	DTAVFECLPQHAMFGnDTITCTTHGnWTK	0.60 ± 0.33	1.42 ± 0.87^c	1.19 ± 0.67^c
		LGn*WSAMPSCK	0.68 ± 0.44	1.16 ± 0.47^c	1.22 ± 0.67^c
		VYKPSAGn*NSLYR	0.67 ± 0.34	1.55 ± 1.21^c	1.18 ± 0.71^c
P20851	C4b-binding protein beta chain	EWDn*TTTECR	0.59 ± 0.26	1.13 ± 0.54^c	1.12 ± 0.63^c
P07339	Cathepsin D light chain	GSLSYLn*VTR	0.81 ± 0.24	1.06 ± 0.23^c	1.10 ± 0.21^c
P02760	cDNA FLJ51445, highly similar to AMBP protein	SKWn*ITMESYVVHTNYDEYAIFLTK	0.83 ± 0.46	1.52 ± 0.88^c	1.71 ± 0.88^c
P00450	Ceruloplasmin	EHEGAIYPDn*TTDFQR	0.75 ± 0.32	1.10 ± 0.37^c	1.05 ± 0.30^c
		En*LTAPGSDSAVFFEQGTTR	0.78 ± 0.34	1.14 ± 0.42^c	1.12 ± 0.38^c
Q9NZP8	Complement C1r subcomponent-like protein	n*QSVNVFLGHTAIDEMLK	0.90 ± 0.41	1.55 ± 0.64^c	1.38 ± 0.50^c
Q03591	Complement factor H-related protein 2	LQNNENn*ISCVER	0.53 ± 0.27	1.40 ± 0.79^c	1.26 ± 0.97^c
P05156	Complement factor I light chain	n*GTAVCATNR	0.83 ± 0.26	1.36 ± 0.60^c	1.16 ± 0.45^c
	Contactin-4	SDVGn*YTCVVTNTVTNHK	0.86 ± 0.25	1.06 ± 0.22	1.14 ± 0.18^c
Q02487	Desmocollin-2	An*YTILK	0.71 ± 0.33	0.91 ± 0.33	1.08 ± 0.22^c
Q9H4A9	Dipeptidase 2	GVHSFYNn*ISGLTDFGEK	0.97 ± 0.19	1.25 ± 0.22^c	1.15 ± 0.20^c
Q14118	Dystroglycan	LGAn* GSHIPQTSSVFSIEVYPEDHSELQSVR	0.80 ± 0.23	1.19 ± 0.27^c	1.03 ± 0.17^c
P02790	Hemopexin	ALPQPQn*VTSLLGCTH	0.62 ± 0.25	1.18 ± 0.56^c	1.13 ± 0.34^c
		SWPAVGn*CSSALR	0.70 ± 0.38	1.04 ± 0.44^c	1.21 ± 0.55^c
P05546	Heparin cofactor 2	DFVn*ASSK	0.71 ± 0.35	1.30 ± 0.50^c	1.16 ± 0.50^c
		n*LSMPLLPADFHK	0.71 ± 0.35	1.15 ± 0.40^c	1.07 ± 0.44^c
P26927	Hepatocyte growth factor-like protein alpha chain	GTGn*DTVLNVALLNVISNQECNIK	0.86 ± 0.22	1.14 ± 0.56	1.24 ± 0.35^c
Q9Y6R7	IgGFc-binding protein	VITVQVAn*FTLR	0.74 ± 0.34	1.14 ± 0.89	1.39 ± 0.73^c
		FDFQGTCEYLLSAPCHGPPLGAEn*FTVTVANEHR	0.72 ± 0.35	1.25 ± 0.34^c	1.12 ± 0.39^c
		YLPVn*SSLLTSDCSER	0.79 ± 0.28	1.03 ± 0.60	1.23 ± 0.67^c
O14498	Immunoglobulin superfamily containing leucine-rich repeat protein	FQAFAn*GSLLIPDFGK	0.78 ± 0.19	1.08 ± 0.26^c	1.04 ± 0.30^c
Q06033	Interalpha-trypsin inhibitor heavy chain H3	NAHGEEKEn*LTAR	0.54 ± 0.18	1.25 ± 0.74^c	1.10 ± 0.64^c
P40189	Interleukin-6 receptor subunit beta	EQYTIIn*R(TA)	0.82 ± 0.22	1.03 ± 0.20	1.13 ± 0.31^c
P01042	Kininogen-1	YNSQn*QSNNQFVLYR	0.48 ± 0.37	2.12 ± 3.39^c	1.39 ± 0.84^c
P02750	Leucine-rich alpha-2-glycoprotein	KLPPGLLAn*FTLLR	0.68 ± 0.40	1.65 ± 1.32c	1.49 ± 0.85^a
		MFSQn*DTR	0.66 ± 0.14	1.50 ± 1.08^c	1.02 ± 0.50^c
P51884	Lumican	LSHNELADSGIPGNSFn*VSSLVELDLSYNK	0.78 ± 0.21	1.04 ± 0.15^c	1.00 ± 0.17^c
P22897	Macrophage mannose receptor 1	WECKn*DTLLGIK	0.88 ± 0.45	0.99 ± 0.32	1.37 ± 0.35^c
P01033	Metalloproteinase inhibitor 1	FVGTPEVn* QTTLYQR	0.82 ± 0.25	1.14 ± 0.52	1.19 ± 0.38^c
Q92859	Neogenin	TLSDVPSAAPQn*LSLEVR	0.73 ± 0.15	1.09 ± 0.31^c	1.02 ± 0.16^c
P55058	Phospholipid transfer protein	IYSn*HSALESLALIPLQAPLK	0.82 ± 0.24	1.11 ± 0.40	1.05 ± 0.24^c
P05155	Plasma protease C1 inhibitor	VLSn*NSDANLELINTWVAK	0.90 ± 0.34	1.43 ± 0.69^c	1.33 ± 0.57^c
P01833	Polymeric immunoglobulin receptor	VPGn*VTAVLGETLK	0.62 ± 0.29	1.34 ± 0.84^c	1.15 ± 0.74^c
P41222	Prostaglandin-H2 d-isomerase	WFSAGLASn*SSWLR	0.88 ± 0.34	1.20 ± 0.93	1.58 ± 0.85^c
		SVVAPATDGGLn*LTSTFLR	0.82 ± 0.38	1.08 ± 0.87	1.29 ± 0.66^c
Q86VB7	Scavenger receptor cysteine-rich type 1 protein M130	CKGn*ESSLWDCPAR	0.74 ± 0.35	1.07 ± 0.49	1.10 ± 0.26^c
P01009	Short peptide from AAT	ADTHDEILEGLNFn*LTEIPEAQIH	0.50 ± 0.17	0.80 ± 0.55	0.90 ± 0.34^c
	Thyroxine-binding globulin	VTACHSSQPn*ATLYK	0.71 ± 0.33	1.08 ± 0.32^c	1.09 ± 0.58^c
P00751	Uncharacterized protein	SPYYn*VSDEISFHCYDGYTLR	0.75 ± 0.39	1.22 ± 0.93	1.28 ± 0.53^c
P04004	Vitronectin	Nn*ATVHEQVGGPSLTSDLQAQSK	0.59 ± 0.46	2.70 ± 6.67	1.26 ± 0.79^c
P04275	von Willebrand factor	GLQPTLTNPGECRPn*FTCACR	0.71 ± 0.40	1.02 ± 0.98	1.44 ± 0.84^c
	von Willebrand factor	MEACMLn*GTVIGPGK	0.78 ± 0.22	1.03 ± 0.37	1.30 ± 0.79^c
P25311	Zinc-alpha-2-glycoprotein	FGCEIENn*R(SS)	0.69 ± 0.28	1.48 ± 1.08	1.29 ± 0.43^c
		DIYEYYn*DSNGSHVLQGR	0.78 ± 0.21	1.02 ± 0.38	1.04 ± 0.37^c
P05154	Plasma serine protease inhibitor	VLPSLGISNVFTSHADLSGISn*HSNIQVSEMVHK	0.78 ± 0.42	1.02 ± 0.54	1.23 ± 0.39^c

Data represent the mean and SD value based on the reporter ion ratios for CF proteins quantified in at least 5 sample sets. Significant difference level P ≤ 0.05; N, healthy controls; CP, chronic pancreatitis; PC, pancreatic cancer; SR, standard reference.

Asterisk (*) indicates CF modification at asparagine (n) residue.

Difference between healthy controls and pancreatic cancer or chronic pancreatitis.

Table 2. List of Differentially Expressed CF Peptides between Healthy Control Samples and Pancreatic Cancer or Chronic Pancreatitisa.

Table 2. List of Differentially Expressed CF Peptides between Healthy Control Samples and Pancreatic Cancer or Chronic Pancreatitis^a.